Phase 1 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 to 75 years old.
- People who are willing to sign a consent form agreeing to take part voluntarily.
- People who have been diagnosed with ovarian cancer confirmed by laboratory testing of tissue, with no need for an additional biopsy during the screening period.
- People with platinum-resistant recurrent ovarian cancer — meaning their cancer initially responded to at least 4 cycles of platinum-based chemotherapy, but then came back or worsened between 28 days and 6 months after their last platinum-based treatment, and who have had at least one further treatment since then, with no more than 3 total prior lines of treatment overall (confirm with trial site for how prior treatments are counted).
- People with a general health and activity level rated between 0 and 2 on a standard medical scale, meaning they are fully active to capable of limited self-care (confirm with trial site).
- People with a life expectancy of at least 3 months.
- People whose blood, liver, kidney, and clotting function results fall within acceptable ranges on tests taken within 14 days before starting treatment, without having needed a blood transfusion or growth factor support in the 14 days before those tests (confirm with trial site for specific values).
- People who have at least one measurable area of disease visible on imaging, as defined by standard medical measurement criteria.
- People of childbearing potential who agree to use effective contraception from the time of signing the consent form until at least 6 months after the last dose of the study treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have taken part in another clinical drug trial within the 4 weeks before enrolling.
- People whose ovarian cancer is of a non-epithelial type.
- People who have received any cancer treatment — including chemotherapy, radiation, targeted therapy, hormone therapy, biological therapy, immunotherapy, herbal cancer treatments, or other investigational treatments — within 28 days or 5 half-lives of the study drug (whichever is shorter) before the first dose.
- People who have had radiotherapy within 4 weeks before the first dose, or palliative radiation to bone within 2 weeks before the first dose.
- People who have had major surgery within 4 weeks before the first dose and have not fully recovered, or who have planned surgery scheduled during the trial.
- People who have had another cancer in the past 5 years, with some exceptions such as certain treated skin cancers or other solid tumours with no sign of disease for more than 5 years (confirm with trial site).
- People who still have side effects from previous treatments that have not returned to their normal baseline or to a mild level, except for effects considered by the treating doctor to pose no safety risk, such as hair loss.
- People with active or uncontrolled spread of cancer to the brain or the lining around the brain, where the treating doctor considers participation inappropriate.
- People who are HIV positive, have active hepatitis B virus (unless successfully treated with antiviral medication), have active hepatitis C virus, or test positive for syphilis antibodies.
- People with an active infection that requires systemic antibiotic, antiviral, or antifungal treatment, as determined by the treating doctor.
- People who are pregnant or breastfeeding.
- People with a known history of drug, alcohol, or substance misuse, or a confirmed history of neurological or psychiatric disorders.
- People with an active autoimmune disease, a history of autoimmune disease, or a history of acquired immune deficiency syndrome (AIDS).
- People who have used corticosteroids above a certain dose (more than 10 mg per day of prednisone or equivalent) or other immune-suppressing medications within 4 weeks before the study drug, or who would need long-term systemic steroids during the trial (topical steroids are allowed).
- People with serious or poorly controlled heart conditions, including severe or unstable chest pain, symptomatic heart failure, significant heart rhythm problems requiring treatment, or a heart attack within the 6 months before the first dose.
- People with high blood pressure that remains poorly controlled despite medication, specifically a systolic reading of 150 mmHg or higher and/or a diastolic reading of 100 mmHg or higher.
- People with poorly controlled diabetes, certain metabolic conditions, serious gastrointestinal bleeding, severe diarrhoea, or serious bowel obstruction requiring intervention (confirm with trial site for specific definitions).
- People with serious lung disease, including breathlessness at rest, a need for continuous oxygen, or a history of a lung condition called interstitial lung disease.
- People with a known allergy to the study drug, its main ingredients, or to kanamycin (an antibiotic).
- People who have had a blood clot, stroke, bleeding disorder, or signs of a tendency to bleed within the 6 months before the first dose.
- People with any other serious or uncontrolled medical condition that the treating doctor considers would make participation unsafe or unsuitable.
- People of childbearing potential who are unwilling to use effective contraception during the trial and for 6 months after treatment ends; people who have stopped having periods due to cancer treatment may still be required to take a pregnancy test (confirm with trial site).
- People who have a bowel stoma or bowel obstruction.
- People with abdominal adhesions or infection that would prevent the study drug from being given into the abdominal cavity.
- People whose physical condition makes intraperitoneal injection unsuitable, or who have other factors that the treating doctor believes would prevent them from completing the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If this is close to home
This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.
- Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
- Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
- Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
- Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
- Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14
Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.
Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Phone: +86 028-85421141
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Dose-escalation part: Observation of DLT; Dose-escalation part: Determination of the MTD or MAD
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.